Member Info for HarriM

Wrong company, sorry!

Was just looking through the presentations, and the results were positive from part A of the trial. They then started recruiting for B. Why would they have two presentations/ posters which were included relatively last minute (news, Aug 2nd) unless there is additional positive data from Keytruda + DDDD's bacterium. Looking forward to the news preceding the 16th. It must be worthy of an RNS, they've already stated this.

Refers to identified benefits, positive readout incoming. Furthermore permission to be authorised from all stakeholders. Wouldn't be needed unless positive and pharma interested.

https://rover-labs.com/article-prnewsire

Cloud Lis, designed for the Mologic test, as part of RdX, can automatially send test results to goverment agencies to meet contact tracing reqs.

The EUA forms were submitted at the end of July/ beginning of last month, this is approx turnaround time now. UK tests only passed in the last six weeks. Cloud-based system customisation for the Mologic test is recent. Buy out of Mologic by Bill Gates ect only just preceded this, so several signs are there

We're entering a news rich period- EUA for Visitect/ Mologic test in the US, shored up by the Bill and Melinda Gates foundation and RadX, multiple signals (Mologic US lease, Columbia University RADX (US-NIH) software bespoke for home testing specifically for the Mologic test, signs are there that this will be given anyday, and incoming US revs. Then also the GOVT contract for a UK test. Numerous MPs have stated a UK test has passed PD criteria so again forthcoming, I think this is probably the Surescreen test, but the manufacturing revs will be a gamechanger and with schools back and cases rising, this is highly likely to be ramped up asap

In addition to exclusive self antibody test manufactiure, TT due on the Avcta antigen test, should be any day now. 'The Board anticipates ALLof these products will contribute meaningfully to contract manufacturing revenue growth in FY 21/22.' So still all go.Also they have made their own test semi-quantitative and this should be in the public domain shortly.

Hats off to them. The high commision has serious reach and 16000 followers. Plus they really emphasis the cutting edge tech and 99.9% 7hrs killing of the virus, I think a lot could come from this, very very good publicity

This test is targeting surface antigen. Once the individual has mounted an antigen-specific immune response by producing antibodies, CD T helper cells ect (this is usually later in the infection), the antigen is usually internalised or degraded and so shouldn't be present and so shouldn't give a positive signal. PCR tests detect specific sections of viral DNA using primer pairs, the DNA can be around for a while later (it's a stable molecule) although it will be eventually cleared in healthy individuals. This is why PCR can give these false +ve tests.

This test is targeting surface antigen. Once the individual has mounted an antigen-specific immune response by producing antibodies, CD T helper cells ect (this is usually later in the infection), the antigen is usually internalised or degraded and so shouldn't be present and so shouldn't give a positive signal. PCR tests detect specific sections of viral DNA using primer pairs, the DNA can be around for a while later (it's a stable molecule) although it will be eventually cleared in healthy individuals. This is why PCR can give these false +ve tests.

RNS states that the hole ended with gold at 251m?

*had, and by a long way. 10m in total compared to 150-170m for the holes towards the west

http://www.rns-pdf.londonstockexchange.com/rns/0204E_1-2020-2-25.pdf

If you look at this map and resuts from Feb 2020, the core published yesterday and the least mineralisation of all the holes drilled.

According to the ASU, Mologic's lateral flow antigen test has to be analysed in a lab setting, very strange if true. Either way, their test will be ready for commercial sales at the end of the year/ start of next. We are already producing the test with BBI. Just waiting on data from CONDOR. Looking at the CONDOR timelines for other lateral flow assays (albeit antibody lateral flow) data should be ready within the next week. Info on Avacta and Mologic LFT can be found at https://chs.asu.edu/diagnostics-commons/testing-commons

The information in the original post is from the ODX Q and A, where they talk about their partnership with Mologic

MR.Spacetomato- I'm an investor in Avacta- you've read my post incorrectly. I'm saying they only have CE marking for the first and the antigen test is three months away from commercial sales. I would expect this test to be ready to sell in a month

Also this is an independent trial by Heathrow, on airport workers not a clinical validation using affected individuals vs. controls. Almost like a first round of validation outside of the laboratory.

Expecting commercial sales of AVCT test within the next month, validation should be complete within a week and CONDOR will accelerate CE marking ect. whilst BBI are already manufacturing.

Contract manufacturing arrangement for four Mologic tests:

– Mologic COVID-19 lab-based ELISA antibody test
– Mologic COVID-19 lab-based ELISA antigen test
– Mologic lateral flow antigen test
– Mologic lateral flow antibody test

The first is CE marked and we’ve shipped our first orders, with evaluations being undertaken in 15 countries. The others are in the process of technical transfer and will then gain CE marking – looking at being ready for commercial sales in Sept (Mologic lateral flow antibody test), October / November (Mologic COVID-19 lab-based ELISA antigen test) and a further two months later (Mologic lateral flow antigen test).

The Abbott rapid test is much-needed by the US step and will reduce the spread of CV19
It has limitations:
1. Can only be ordered by a physician, only be used in a clinical setting and by a clinician at that, limiting its ease of use
2. Test is by nasopharyngeal swab- if you've had a CV19 test in the UK, you know it's not pleasant
3. No over-the-counter/ home-use approval -again major limitation
4. S/s values are in thev. good range, as you'd expect for symptomatic individuals
5. No data published for asymptomatic cases- I would expect this to be lower for most rapid antigen-based tests, however good. In actual fact, even if the sensitivity data for this test was 80% for asymptomatic, would still be good. The fact they haven't published this data is a major red flag.

Having said that all their tests until at least December are for the US, who will almost certainly still require further testing capacity. A way to increase detection in asymptomatic would be to run two different inexpesive rapid tests in parallel, so we could also be of use in this scenario